Form S-1
We note your revised disclosure in response to our prior comment 2 which states that the royalties under the agreement with uniQure are payable until the expiration of the last licensed patent from UBC. Please revise your disclosure regarding the royalty term to provide the expiration date of the last licensed patent from UBC.
The Company respectfully advises the Staff that, as disclosed on page 112 of the Registration Statement, the latest expiration date of the in-licensed patents from UBC is June 2020 (absent any extensions of term) and the latest expiration date of the in-licensed patent applications from UBC is expected to be 2020 (absent any extensions of term).Read in the replyRest of the answer
Accordingly, absent any extensions of the relevant patent terms, the license agreement with UBC shall expire in 2020, upon which the uniQure agreement is also expected to terminate.
Furthermore, regarding the expiration of the royalty terms under the agreement with uniQure, the Company respectfully submits that, as discussed in the Company’s response to comment 5 to the Staff’s letter dated October 4,
Page
2013, licensed patents under the UBC agreement include several patents that are in various stages of prosecution in numerous countries and the terms of which could be extended. Accordingly, providing estimated durations of the royalty terms under the uniQure agreement based on an anticipated year of expiration of the UBC in-licensed patents brings with it a significant likelihood of inaccurately reflecting the actual royalty term as, for example, certain patent applications may not issue and additional patents may be filed that fall within the scope of the UBC agreement. Given the potential changes in the term of the UBC in-licensed patents and other related uncertainties, the
Company respectfully submits that disclosure of the year that a royalty term expires would not be helpful to an investor and could potentially be misleading.
We note your disclosure which states that on March 2014, you entered into an additional agreement with Genentech for pain genetics. Please expand your disclosure to describe the material terms of the agreement, including the parties’ rights and obligations, duration, termination provisions, and any royalties within a ten percent range (e.g., single digits, teens, twenties, etc…).Rest of the question
Also, please file the agreement as an exhibit pursuant to Item 601(b)(10) of Regulation S-K.
to the Staff’s comment, the Company proposes to revise the disclosure on page 111 of the Registration Statement as follows in connection with its submission of an amendment to the Registration Statement (deleted language shown in strike through and added language underlined):Read in the reply
“In March 2014, we entered into an additional agreement with
Genentech for pain genetics, where we intend to use our Extreme Genetics discovery platform to focus on identifying genetic targets associated with rare phenotypes where individuals have an inability to perceive pain or where individuals have non-precipitatedRest of the answer
spontaneous severe pain. Pursuant to the terms of this agreement, any intellectual property arising out of the collaboration will be jointly owned by us and Genentech. We have also granted Genentech a time-limited, exclusive right of first negotiation on a target-by-target basis to form joint drug discovery collaborations. Under the terms of this agreement, Genentech paid us an upfront payment of $1.5 million. In addition, and wWe are eligible for an additional $2.0 million in milestone payments. The agreement terminates upon the expiration of Genentech’s time-limited, exclusive right of first negotiation which shall be exercisable for two years. Genentech may terminate the agreement with three months advance notice anytime on or after the 12 month anniversary of the effective date of the agreement, and each party may terminate the agreement in the event of a material breach by the other party that remains uncured for 90 days., and Furthermore, at our option, a Genentech affiliate will invest up to $5.0 million in a private placement concurrent with this public offering at the same price per share as this public offering. The option to invest will expire if the public offering does not occur by December 31, 2014.”
The Company respectfully advises the Staff that, notwithstanding the foregoing, the March 2014 agreement is not material to the Company, the existing disclosure regarding the agreement, as revised above, is sufficient for an agreement of this nature and that disclosure of the additional details requested would neither be helpful to an investor nor would disclosure of such details alter the total mix of information available regarding the Company.
The March 2014 agreement was made in the ordinary course of business and the Company’s business is not substantially dependent on such agreement as the total amount which can be earned under the agreement is $3.5 million, $1.5 million of which has been received by the Company as an upfront payment. The existing description on pages 64 and 111 of the Registration Statement already provides the following details:
•
The maximum amount payable to the Company pursuant to upfront and milestone payments;
A description of the genetic target identification work the Company will perform pursuant to the agreement;
Joint ownership by the Company and Genentech for any intellectual property arising out of the collaboration; and
A grant of a time-limited, exclusive right of first negotiation to Genentech on a target-by-target basis.
Furthermore, the Company supplementally advises the Staff that the agreement does not contain any royalty provisions.
Given the foregoing details, the Company respectfully submits that the March 2014 agreement is not material to the Company, but that the disclosure provides additional evidence to investors of the Company’s execution on its strategy of forming collaborations for the advancement of its product pipeline. For the foregoing reasons, the Company believes that the new agreement with Genentech is not a material contract within the meaning of Item 601(b)(10) of Regulation S-K.
Please expand your disclosure regarding the patent applications which you co-own for GDC-0276 to identify with whom you co-own these patent applications and the foreign jurisdictions where the applications are pending.
to the Staff’s comment, the Company proposes to revise the disclosure on page 112 of the Registration Statement as follows in connection with its filing of an amendment to the Registration Statement (deleted language shown in strike through and added language underlined)Read in the reply
“As of June 30 September 30, 2014 we, together with
Genentech, co-owned two pending U.S.Rest of the answer
patent applications, one pending PCT international patent application and three corresponding patent applications in various foreign jurisdictions Argentina, Taiwan and the
Cooperation Council for the Arab States of the Gulf relating to GDC-0276 and methods of making and using this and certain related compounds. Any patents issuing from these applications are expected to expire in 2033 (absent any extensions of term).”
We note your updated principal shareholders table to June 30, 2014 in response to our prior comment 4. Please revise the principal shareholders table so that it is as of the latest practicable date within two weeks of the filing date of your amended the registration statement.
Company acknowledges the Staff’s comment and will update the principal shareholders table with its filing of an amendment to the Registration Statement so that it is as of the latest practicable date within two weeks of the filing date.Read in the reply
On page F-17, you state “Each of the Series A, Series B and Series E preferred shares will automatically convert into common shares in connection with an IPO satisfying certain threshold requirements.” Please disclose these threshold requirements in the notes to the financial statements, and expand your pro forma disclosures throughout the filing to explain why assuming that the convertible preferred stock will beRest of the question
converted into common stock is factually supportable. Refer to rule 11-02(b)(6) of Regulation S-X.
The Company advises the Staff that it has revised the disclosure on pages F-8 and F-17 in response to the Staff’s comment.Read in the reply
The Company further supplementally advises the Staff that the Company has received consents from the requisite number of holders of
Series A, Series B and Series E preferred shares, as prescribed in the articles of the Company, to effect the conversion of all outstanding Series A, Series B and Series E preferred shares into common shares prior to the closing of the offering upon approval of the Company’s board of directors.Rest of the answer
Consequently, the Company advises the Staff that there are no longer any threshold requirements that must be satisfied in order for all of
Securities and Exchange Commission
Page the outstanding Series A, Series B and Series E preferred shares to be converted into common shares. As such, the Company advises the Staff that it has revised the Registration Statement as discussed above to remove reference to the threshold requirements prior to the automatic conversion of the Company’s preferred shares to common shares.
Also in this review: company letter, Sep 29, 2014, company letter, Oct 14, 2014, company letter, Oct 14, 2014, company letter, Nov 3, 2014